The Coca-Cola Co K vs Novavax Inc — how do they compare? The Coca-Cola Co K trades at $86.36 (market cap $373.76B), while Novavax Inc trades at $7.95 (market cap $1.30B). The key difference: The Coca-Cola Co K is far larger — about 287.5× Novavax Inc's market cap, and The Coca-Cola Co K pays a 2.44% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| KO | NVAX | |
|---|---|---|
Market Cap | $373.76B | $1.30B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $89.08 | $11.19 |
52-Week Low | $65.67 | $6.22 |
Enterprise Value | $400.93B | $879.40M |
Dividend Yield | 2.44% | — |
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $86.87, down 0.21% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.97 exceeding the $0.92 forecast. Key valuation ratios include a P/E of 26.09 and ROE of 44.23%, while cash flow trends show robust operational performance. Recent news highlights institutional buying and stable demand trends ahead of Q3 earnings.
The outlook remains positive with a consensus price target of $95.83, implying 10.3% upside. Strengths include a 64-year dividend growth streak and high profitability, but risks involve regional demand divergence and elevated debt levels. Analyst sentiment is bullish with 60% buy ratings, supporting a favorable investment case for long-term holders.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →